Fate Therapeutics (FATE)
(Delayed Data from NSDQ)
$3.76 USD
+0.10 (2.73%)
Updated Jun 5, 2024 04:00 PM ET
After-Market: $3.76 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Fate Therapeutics, Inc. [FATE]
Reports for Purchase
Showing records 381 - 400 ( 432 total )
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov. 2This report contains brief updates on the following: DYAX, ANAC, IRWD, ECYT, FATE, XNCR, RGLS, MGNX, FCSC, SNSS, INFI, MDVN, RPTP, SRPT, XOMA, AGTC, EPZM, BLUE, PTCT, CATB, EPRS, ABUS, ICPT. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Highlights from the Meeting on the Mesa: Looking Beyond Stem Cells in Regenerative Medicine
Provider: H.C. Wainwright & Co., Inc.
Analyst: BREIDENBACH M
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q15 Update-Forays into Cellular Immunotherapy and Multiple Clinical Readouts Could Drive Shareholder Value
Provider: H.C. Wainwright & Co., Inc.
Analyst: BREIDENBACH M
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2:EPS; Pivotal Trial Data Ahead; Building Broad Pipeline with Expanding Network of Collaborators
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
T-Cell Therapy Update: Companies Look Ahead to New Generation of TCell Therapies with Technology Enhancement Deals
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
T-Cell Therapy Update: Companies Look Ahead to New Generation of TCell Therapies with Technology Enhancement Deals
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q15 Update-Peek at PUMA Portends PROHEMA Potency; Raising PT
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: BENJAMIN R
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1:15 EPS; Key Data Readouts on Track for 2H:15, Building a Diverse Pipeline
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Collaboration with Juno Strong Validation of Fate''s Platform; Updated PUMA study Results
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive PUMA Interim Readout and Steering the Fate of Adoptive T-Cell Therapies
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: BENJAMIN R
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4:14 EPS: Pivotal Year of Data Readouts Ahead for FATE, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q14 Update-Multiple Trials Fated for 2015 Readout
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: BENJAMIN R
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events from the Week of March 9th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ProHema Passes Second Interim Review in PUMA, Awaiting Final Data in Mid-15, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES AND HEALTH CARE-The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec 15
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L